91 related articles for article (PubMed ID: 33047324)
1. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
[TBL] [Abstract][Full Text] [Related]
2. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
[TBL] [Abstract][Full Text] [Related]
3. Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma.
Malleo G; Salvia R; Maggino L; Marchegiani G; D'Angelica M; DeMatteo R; Kingham P; Pulvirenti A; Sereni E; Jarnagin WR; Bassi C; Allen PJ; Butturini G
Ann Surg Oncol; 2021 Jun; 28(6):3100-3108. PubMed ID: 33575870
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
[TBL] [Abstract][Full Text] [Related]
5. The results of surgery for renal cell carcinoma metastases of the pancreas.
Riemenschneider KA; Farooqui W; Penninga L; Storkholm JH; Hansen CP
Scand J Gastroenterol; 2024 Mar; 59(3):354-360. PubMed ID: 38042983
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Metastasectomy-an Analysis of Survival Outcomes and Prognostic Factors.
Chua TC; Petrushnko W; Mittal A; Gill AJ; Samra JS
J Gastrointest Surg; 2016 Jun; 20(6):1188-93. PubMed ID: 26892167
[TBL] [Abstract][Full Text] [Related]
7. Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital.
Tosoian JJ; Cameron JL; Allaf ME; Hruban RH; Nahime CB; Pawlik TM; Pierorazio PM; Reddy S; Wolfgang CL
J Gastrointest Surg; 2014 Mar; 18(3):542-8. PubMed ID: 24163138
[TBL] [Abstract][Full Text] [Related]
8. Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study.
Choi J; Bang S; Suh J; Choi CI; Song W; Yuk HD; Lee CH; Kang M; Choo SH; Kim JK; Lee HH; Jo JK; Hwang EC; Jeong CW; Ko YH; Park JY; Song C; Seo SI; Chung J; Kwak C; Hong SH
Sci Rep; 2024 Feb; 14(1):4740. PubMed ID: 38413653
[TBL] [Abstract][Full Text] [Related]
9. Natural history of bone-only metastasis in renal cell carcinoma.
Tang B; Duan R; Fan Z; Yan X; Li S; Zhou L; Li J; Xu H; Mao L; Lian B; Wang X; Bai X; Wei X; Li C; Cui C; Si L; Chi Z; Guo J; Sheng X
Urol Oncol; 2024 Apr; 42(4):119.e17-119.e22. PubMed ID: 38383241
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic resection for metastasis from renal cell carcinoma: A single institution experience and meta-analysis of survival outcomes.
Hajibandeh S; Hajibandeh S; Romman S; Ghassemi N; Evans D; Laing RW; Durkin D; Athwal TS
Pancreatology; 2024 Feb; 24(1):160-168. PubMed ID: 38012888
[TBL] [Abstract][Full Text] [Related]
11. Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review.
Tayeh GA; Alkassis M; De La Taille A; Vordos D; Champy CM; Pelegrin T; Ingels A
World J Urol; 2024 Jan; 42(1):51. PubMed ID: 38244094
[TBL] [Abstract][Full Text] [Related]
12. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID).
Rojas-Holguín A; Fondevila-Campo C; Sanjuanbenito A; Fabregat-Prous J; Secanella-Medayo L; Rotellar-Sastre F; Pardo-Sánchez F; Prieto-Calvo M; Marín-Ortega H; Sánchez-Cabús S; Diez-Valladares L; Alonso-Casado Ó; González-Serrano C; Rodríguez-Sanjuan JC; García-Plaza G; Jaén-Torrejimeno I; Suárez-Muñoz MÁ; Becerra-Massare A; Rio PS; Pando E; López-Andújar R; Muñoz-Forner E; Rodriguez-López M; Pereira F; Serrablo-Requejo A; Turrión VS; Garrido MJ; Burdío F; Martín-Pérez E; Estevan-Estevan R; López-Guerra D; Castell-Gómez J; Salinas-Gómez J; López-Baena JÁ; López-Ben S; Solar-García L; Pérez-Alonso AJ; Martínez-Insfran LA; Blas JL; Cornejo M; Gutierrez-Calvo A; Pozo CD; Ochando-Cerdan F; Muñoz-Bellvís L; Rebollar-Saenz J; Sánchez B; Jover JM; Gómez-Bravo MÁ; Ramia JM; Blanco-Fernández G
Surg Oncol; 2024 Feb; 52():102039. PubMed ID: 38301449
[TBL] [Abstract][Full Text] [Related]
13. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Gebrael G; Meza L; Li X; Zengin Z; Sayegh N; Ebrahimi H; Tripathi N; Castro D; Mercier B; Barragan-Carrillo R; Li H; Chehrazi-Raffle A; Swami U; Tripathi A; Agarwal N; Maughan BL; Pal SK
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38580524
[TBL] [Abstract][Full Text] [Related]
14. The impact of metastasectomy on survival of patients with synchronous metastatic renal cell cancer in Finland: A nationwide study.
Laru L; Ronkainen H; Ohtonen P; Vaarala MH
Scand J Surg; 2024 Mar; ():14574969241234485. PubMed ID: 38433655
[TBL] [Abstract][Full Text] [Related]
15. Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma.
Nagaraja H; Srivatsa N; Hemalatha S; Shweta S; Raghunath SK
Indian J Surg Oncol; 2018 Mar; 9(1):105-109. PubMed ID: 29563747
[TBL] [Abstract][Full Text] [Related]
16. Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study.
Duarte C; Hu J; Beuselinck B; Panian J; Weise N; Dizman N; Collier KA; Rathi N; Li H; Elias R; Martinez-Chanza N; Rose TL; Harshman LC; Gopalakrishnan D; Vaishampayan U; Zakharia Y; Narayan V; Carneiro BA; Mega A; Singla N; Meguid C; George S; Brugarolas J; Agarwal N; Mortazavi A; Pal S; McKay RR; Lam ET
EClinicalMedicine; 2023 Jun; 60():102018. PubMed ID: 37304495
[TBL] [Abstract][Full Text] [Related]
17. State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma.
Dason S; Lacuna K; Hannan R; Singer EA; Runcie K
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390038. PubMed ID: 37253211
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Appleman LJ; Kim SE; Harris WB; Pal SK; Pins MR; Kolesar J; Agarwal N; Parikh RA; Vaena DA; Ryan CW; Hashmi M; Costello BA; Cella D; Dutcher JP; DiPaola RS; Haas NB; Wagner LI; Carducci MA
J Clin Oncol; 2024 Mar; ():JCO2301544. PubMed ID: 38531002
[TBL] [Abstract][Full Text] [Related]
19. Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure.
Kanzaki R; Kanou T; Ose N; Funaki S; Minami M; Tajima T; Fujii M; Ohno Y; Shintani Y
World J Surg; 2019 Oct; 43(10):2640-2646. PubMed ID: 31243525
[TBL] [Abstract][Full Text] [Related]
20. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma.
Strizova Z; Bartunkova J; Smrz D
Cancer Immunol Immunother; 2019 Nov; 68(11):1831-1838. PubMed ID: 31222485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
